

Proposal Evaluation Form

Associated with document Ref. Ares(2018)1509427 - 19/03/2018

	EUROPEAN COMMISSION Horizon 2020 - Research and Innovation Framework Programme	Evaluation Summary Report
---	--	--------------------------------------

Call: H2020-SMEInst-2018-2020-1
Funding scheme: SME-1
Proposal number: 816466
Proposal acronym: Para-T System
Duration (months): 6
Proposal title: The Para-T System A quick blood group device to match in situ the donor bag and the receptor arm during a blood transfusion, avoiding major incompatible errors.
Activity: EIC

N.	Proposer name	Country	Total Cost	%	Grant Requested	%
1	Proposit Bio SL	ES	71,429	100.00%	50,000	100.00%
Total:			71,429		50,000	

Abstract:
The Para-T System

"A quick blood group device to match in situ the donor bag and the receptor arm during a blood transfusion, avoiding major incompatible errors".

The Para-T system is a double identifier device (two plastic cassettes) designed on the one side, to be attached to a bag containing whole blood or Red Blood Cells and on the other, to the catheter inserted in the patient vein allowing a direct, quick (less than a minute) and permanent blood group identification (ABO typing).

The ABO tests in the bag and in the patient' catheter is kept visible from the donation moment till the end of the patient hospitalization, allowing a visual comparison of the blood groups between both cassettes and detecting labelling errors. The technology reduces 4 ABO re-checking during the blood component processing (from a total of 7) reducing staff costs. Combining bag and patient cassettes, the Para-T system conforms a Transfusional Safety System that prevent ABO incompatible transfusions by means of a visual checking (simple solution) or using a PDA QR code reader that controls a solenoid valve incorporated in the tubing system to prevent automatically the transfusion if both bloods are incompatible (complex solution).

The performance of the proposed Safety System is as efficient to avoid mistakes as the most advanced electronic solutions based on personalized wristbands and a sophisticated supportive software offered by some large pharmaceutical firms, but at one tenth of the cost.

The market applications for the new Transfusional Safety Solution are huge as many developing and developed countries cannot afford the expensive electronic solutions and Para-T brings a cheap option to the marketplace with equal or even superior performance.

Evaluation Summary Report

Evaluation Result

Total score: 13.39 (Threshold: 13)

Form information

Indicative Appraisal Scale per Sub-Criterion:

- Very Good to Excellent (4.5 - 5)
- Good to Very Good (3.5 - 4.49)
- Fair to Good (2.5 - 3.49)
- Insufficient to Fair (1.5 - 2.49)
- Insufficient (0-1.49)

* mandatory fields

Criterion 1 - Impact

Score: **4.60** (Threshold: 4/5.00 , Weight: -)

The following aspects have been taken into account:

Convincing description of substantial demand (including willingness to pay) for the innovation; demand generated by new ideas, with the potential to create new markets, is particularly sought after.

Total market size envisaged.

Very Good to Excellent (4.5 - 5)

Convincing description of targeted users or customers of the innovation, how their needs have been addressed, why the users or customers identified will want to use or buy the product, service or business model, including compared to what is currently available if anything at all.

Very Good to Excellent (4.5 - 5)

Good understanding of need for a realistic and relevant analysis of market conditions, total potential market size and growth-rate,

competitors and competitive offerings, key stakeholders, clear identification of opportunities for market introduction, potential for market creation is particularly sought after. 2018/12/18

Very Good to Excellent (4.5 – 5)

Realistic and relevant description of how the innovation has the potential to scale-up the applicant company (or companies). This should be underpinned by a convincing business plan with a clear timeline, and complemented, where possible, by a track-record that includes financial data.

Very Good to Excellent (4.5 – 5)

Alignment of proposal with overall strategy of applicant SME (or SMEs) and commitment of the team behind them. Demonstration of need for commercial and management experience, including understanding of the financial and organisational requirements for commercial exploitation and scaling up.

Very Good to Excellent (4.5 – 5)

Outline of initial commercialisation plan and how this will be developed further (in-house development, licensing strategy, etc.).

Good to Very Good (3.5 – 4.49)

European/global dimension of innovation with respect to both commercialisation and assessment of competitors and competitive offerings.

Very Good to Excellent (4.5 – 5)

Realistic and relevant description of knowledge protection status and strategy, need for 'freedom to operate' (i.e., possibility of commercial exploitation), and current IPR situation. Where relevant, description of potential regulatory requirements.

Good to Very Good (3.5 – 4.49)

Taken as whole, to what extent the above elements are coherent and plausible

Very Good to Excellent (4.5 – 5)

Criterion 2 - Excellence

Score: **4.15** (Threshold: 4/5.00 , Weight: -)

The following aspects have to be taken into account.

High-risk/high-potential innovation idea that has something that nobody else has. It should be better and/or significantly different to any alternative. Game-changing ideas or breakthrough innovations are particularly sought after. Its high degree of novelty comes with a high chance of either success or failure.

Good to Very Good (3.5 – 4.49)

Realistic description of the current stage of development and clear outline of the steps planned to take this innovation to market.

Good to Very Good (3.5 – 4.49)

Highly innovative solution that goes beyond the state of the art in comparison with existing or competing solutions, including on the basis of costs, ease of use and other relevant features as well as issues related to climate change or the environment, the gender dimension, any other benefits for society, or (Phase 1 only) includes plans for obtaining this information.

Good to Very Good (3.5 – 4.49)

Very good understanding of both risks and opportunities related to successful market introduction of the innovation from both technical and commercial points of view or (Phase 1 only) includes convincing plans for obtaining this information.

Good to Very Good (3.5 – 4.49)

Objectives for the feasibility study and the approach and activities to be developed are consistent with the expected impact of the innovation.

Good to Very Good (3.5 – 4.49)

Taken as whole, to what extent the above elements are coherent and plausible

Good to Very Good (3.5 – 4.49)

Criterion 3 - Quality and efficiency of implementation

Score: **4.50** (Threshold: 4/5.00 , Weight: -)

Technical/business experience of the team, including management capacity to lead a growing team. If relevant, the proposal includes a plan to acquire missing competences.

Good to Very Good (3.5 – 4.49)

Availability of resources required (personnel, facilities, networks, etc.) to develop project activities in the most suitable conditions.

Where relevant, complementarity of partners in a consortium.

Good to Very Good (3.5 – 4.49)

Realistic timeframe and comprehensive description of implementation (work-packages, major deliverables and milestones, risk management) taking the company's or applicant's innovation ambitions and objectives into account.

Very Good to Excellent (4.5 – 5)

Taken as a whole, to what extent are the above elements coherent and plausible.

Good to Very Good (3.5 – 4.49)

Use of human embryonic stem cells (hESC)

Does this proposal involve the use of hESC?

No

If yes, please state whether the use of hESC is, or is not, in your opinion, necessary to achieve the scientific objectives of the proposal and the reasons why. Alternatively, please state if it cannot be assessed whether the use of hESC is necessary or not

because of a lack of information.

 Associated with document Ref. Ares(2018)1509427 - 19/03/2018


Not provided

Scope of the proposal

Status: **Yes**

Comments (in case the proposal is out of scope)

Not provided



This document is digitally sealed. The digital sealing mechanism uniquely binds the document to the modules of the Participant Portal of the European Commission, to the transaction for which it was generated and ensures its integrity and authenticity.

Any attempt to modify the content will lead to a breach of the electronic seal, which can be verified at any time by clicking on the digital seal validation symbol.